Zurich, Jan 24, 2026, 17:10 CET — Market closed.
- Roche’s non-voting shares ended at 348.10 Swiss francs, ticking up 0.06%.
- Full-year 2025 results from the company are set for release before the Swiss market opens on Jan. 29.
- Ahead of their March shareholder meeting, investors are zeroing in on guidance for 2026 and any hints about dividends.
Roche Holding’s non-voting shares ended Friday at 348.10 Swiss francs, rising 0.20 franc. The stock hovered just shy of its 52-week peak during the session.
All eyes turn to Thursday, as Roche plans to unveil its full-year 2025 results before the Swiss Stock Exchange opens. The company announced the report will drop at 07:00 CET, followed by a webinar scheduled for later that day.
The timing is key as the stock edges near the peak of its yearly range, testing investors’ patience amid a cautious outlook. Roche has scheduled a neurology-focused investor event on Feb. 9, which will keep pipeline updates in focus through early February.
Swiss pharma giant Roche is pushing to prove it can expand past its aging blockbusters as patents run out and cheaper biosimilars—close copies of complex biotech medicines—eat into its sales. Last October, a portfolio manager called the growth “lower quality,” while CEO Thomas Schinecker insisted the company was “only scratching the surface” of the obesity market. Reuters
Pricing policy remains a key issue. Following U.S. Medicaid pricing deals last month, Schinecker cautioned that the changes might cause “further delays” in rolling out new medicines in Switzerland if lawmakers push back against higher prices for these drugs. Reuters
Dividend details will follow quickly after the earnings release. Roche’s share and bond info page notes the annual general meeting is scheduled for March 10, where shareholders will decide on the proposed 2025 dividend. It also provides a tentative dividend schedule.
Investors will focus on the key drivers today: overall group sales momentum, the split between newer products and legacy franchises, and the resilience of diagnostics amid a volatile hospital-spending climate.
Thursday’s report could swing either way. The stock is trading close to its highs, so a weaker 2026 forecast, tempered comments on pricing pressure, or another hiccup in late-stage trials might spark profit-taking.
Swiss trading kicks off again Monday, with positioning likely to remain tight ahead of Thursday’s release, following a subdued finish on Friday.
Roche’s full-year results drop before the bell on Jan. 29, with management hosting a webcast later that day. After that, investors’ focus shifts to the Feb. 9 neurology investor event, then onto the shareholder meeting set for March 10.
